Summit Therapeutics Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Summit Therapeutics Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Summit Therapeutics Inc. do? Business model and key facts
Get the full picture of Summit Therapeutics Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 159
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Stocks related to Summit Therapeutics Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Summit Therapeutics Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Summit Therapeutics Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
